Key statistics
On Tuesday, Assembly Biosciences Inc (V7B:STU) closed at 22.70, -32.84% below its 52-week high of 33.80, set on Dec 01, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 22.20 |
|---|---|
| High | 22.80 |
| Low | 22.20 |
| Bid | 22.70 |
| Offer | 23.20 |
| Previous close | 22.40 |
| Average volume | 480.20 |
|---|---|
| Shares outstanding | 15.82m |
| Free float | 10.71m |
| P/E (TTM) | -- |
| Market cap | 425.48m USD |
| EPS (TTM) | -4.81 USD |
Data delayed at least 15 minutes, as of Feb 10 2026.
More ▼
Announcements
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Studies of Long-Acting Helicase-Primase Inhibitor Candidates ABI-1179 and ABI-5366 Showing Reductions in Viral Shedding Rate and Virologically Confirmed Genital Lesion Rate in Recurrent Genital Herpes
- Assembly Biosciences Reports Third Quarter 2025 Financial Results and Recent Updates
- Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
- Assembly Biosciences Announces Upcoming Investor Conference Participation
- Assembly Biosciences Presents Interim Phase 1b Data for HSV Helicase-Primase Inhibitor Candidate ABI-5366 at the 38th Congress of the International Union Against Sexually Transmitted Infections (IUSTI)- Europe
- Assembly Biosciences Announces Pricing of $175 Million in Equity Financings
- Assembly Biosciences Reports Positive Interim Results from Phase 1b Clinical Study of Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366 Showing Reductions in Viral Shedding Rate and Genital Lesion Rate in Recurrent Genital Herpes
- Assembly Biosciences Reports Interim Phase 1a Data from Clinical Study of Oral Entry Inhibitor Candidate ABI-6250 for Hepatitis Delta Virus
- Assembly Biosciences Reports Second Quarter 2025 Financial Results and Recent Updates
- Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop
More ▼
